Officer sold ~$83K of Alkermes plc
Scheduled in advanceLoading…
ALKS · NASDAQ · Pharmaceuticals
Pharmaceuticals company based in Dublin, Ireland.
In the last 90 days, no insider of Alkermes plc reported an open-market purchase and 8 open-market sales worth about $3.75M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$42.76
Last 12 months
Not enough history
Market value
$7.17B
Revenue
$496M
+27.0% vs the same quarter a year earlier
Free cash flow, last 12 months
$222M
This quarter $137M, a year earlier $137M
Net debt
$1.01B
Debt $1.52B, cash $512M, at Jun 30, 2026
Net income, last 12 months
$66.1M
Operating profit covers interest 2x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 28, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
8 sales
$3.75M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$1.48B
−5.2% vs the year before
Net income, fiscal 2025
$242M
As reported in the annual filing
Shares outstanding
168M
As of Jul 23, 2026
In fiscal 2024 the company spent $200M buying back its own shares. Cash actually paid, from its cash-flow statement.
Officer sold ~$83K of Alkermes plc
Scheduled in advanceOfficer sold ~$98K of Alkermes plc
Scheduled in advanceOfficer sold ~$423K of Alkermes plc
Scheduled in advanceOfficer sold ~$33K of Alkermes plc
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $30.99 on Oct 6, 2025 to $42.76 on Oct 5, 2026 (+38.0%). Disclosed activity in the last 12 months: 0 insider purchases, 34 insider sales (32 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.
Top officer leaving
“Pops, Chairman and Chief Executive Officer of Alkermes plc (the “Company”), notified the Company’s board of directors (the “Board”) of his decision to retire from his position of Chief Executive Officer, effective July 31, 2026, following a distinguished 35 years of service in this role.”
2 insiders sold ~$2.68M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.